DUPILUMAB IMPROVES HISTOLOGIC AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS IN CHILDREN AGED 1-11 YEARS IN THE PHASE 3 EOE KIDS TRIAL

被引：0
|
作者：
Chehade, Mirna
Dellon, Evan S.
Spergel, Jonathan
Rothenberg, Marc E.
Liu, Ruiqi
Mannent, Leda
Laws, Elizabeth
Mortensen, Eric
Maloney, Jennifer
Khokhar, Faisel
Beazley, Bethany
Glotfelty, Lila
Shabbir, Arsalan
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
605
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 48 条
  • [31] Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial
    Bredenoord, Albert J.
    Dellon, Evan S.
    Schlag, Christoph
    Cianferoni, Antonella
    Xia, Changming
    Pela, Tiffany
    Durrani, Sandy
    Radwan, Amr
    Jacob-Nara, Juby A.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (02) : 197 - 209
  • [32] Rapid and sustained improvement in itch in children aged 6-11 years with severe atopic dermatitis (AD) treated with dupilumab: analysis from the LIBERTY AD PEDS phase 3 trial
    Yosipovitch, Gil
    Silverberg, Jonathan I.
    Wu, Jashin J.
    Chen, Zhen
    Abramova, Alvina
    Prescilla, Randy
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (01) : 89 - 89
  • [33] Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial
    Elaine C. Siegfried
    Michael J. Cork
    Norito Katoh
    Haixin Zhang
    Chien-Chia Chuang
    Ryan B. Thomas
    Ana B. Rossi
    Sonya L. Cyr
    Annie Zhang
    American Journal of Clinical Dermatology, 2023, 24 : 787 - 798
  • [34] BUDESONIDE ORAL SUSPENSION (BOS) IMPROVES ENDOSCOPIC ACTIVITY IN ADOLESCENTS AND ADULTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS AND CORRELATION ANALYSIS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Hirano, Ikuo
    Collins, Margaret H.
    Katzka, David A.
    Mukkada, Vincent A.
    Falk, Gary W.
    Williams, James
    Desai, Nirav K.
    Lan, Lan
    Dellon, Evan S.
    GASTROENTEROLOGY, 2020, 158 (06) : S42 - S43
  • [35] Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial
    Siegfried, Elaine C.
    Cork, Michael J.
    Katoh, Norito
    Zhang, Haixin
    Chuang, Chien-Chia
    Thomas, Ryan B.
    Rossi, Ana B.
    Cyr, Sonya L.
    Zhang, Annie
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (05) : 787 - 798
  • [36] FLUTICASONE PROPIONATE ORALLY DISINTEGRATING TABLET (APT-1011) IMPROVES HISTOLOGIC, ENDOSCOPIC AND SYMPTOMATIC RESPONSES IN EOSINOPHILIC ESOPHAGITIS PATIENTS WITH FIBRO-STENOTIC FEATURES: RESULTS FROM A PHASE 2B TRIAL
    Dellon, Evan S.
    Falk, Gary W.
    Lucendo, Alfredo
    Schlag, Christoph
    Schoepfer, Alain M.
    Eagle, Gina
    Nezamis, James P.
    Comer, Gail M.
    Knoop, Karol
    GASTROENTEROLOGY, 2021, 160 (06) : S111 - S112
  • [37] EFFECT OF PRIOR ESOPHAGEAL DILATION ON HISTOLOGIC, SYMPTOM AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: POST HOC ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION
    Hirano, Ikuo
    Collins, Margaret H.
    Katzka, David A.
    Mukkada, Vincent A.
    Falk, Gary W.
    Terreri, Brian
    Boules, Mena
    Zhang, Wenwen
    Desai, Nirav K.
    Dellon, Evan S.
    GASTROENTEROLOGY, 2022, 162 (07) : S530 - S530
  • [38] Dupilumab Was Well Tolerated and Significantly Improved Atopic Dermatitis in Children Aged ≥ 6 to < 12 Years: Results From the LIBERTY AD PEDS Phase 3 Trial
    Marcoux, Danielle
    Wu, Jashin J.
    Shumel, Brad
    Ohya, Yukihiro
    Zhang, Annie
    Chen, Zhen
    PEDIATRICS, 2021, 147 (03)
  • [39] Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
    Paller, Amy S.
    Simpson, Eric L.
    Siegfried, Elaine C.
    Cork, Michael J.
    Wollenberg, Andreas
    Arkwright, Peter D.
    Soong, Weily
    Gonzalez, Mercedes E.
    Schneider, Lynda C.
    Sidbury, Robert
    Lockshin, Benjamin
    Meltzer, Steven
    Wang, Zhixiao
    Mannent, Leda P.
    Amin, Nikhil
    Sun, Yiping
    Laws, Elizabeth
    Akinlade, Bolanle
    Dillon, Myles
    Kosloski, Matthew P.
    Kamal, Mohamed A.
    Dubost-Brama, Ariane
    Patel, Naimish
    Weinreich, David M.
    Yancopoulos, George D.
    O'Malley, John T.
    Bansal, Ashish
    LANCET, 2022, 400 (10356): : 908 - 919
  • [40] Efficacy and safety of dupilumab in children aged 6-11 years with inadequately controlled severe atopic dermatitis: results from an open-label extension trial up to 1 year
    Paller, A. S.
    Cork, M. J.
    Siegfried, E. C.
    Guttman-Yassky, E.
    Simpson, E. L.
    Soong, W.
    Xiao, J.
    Wang, Z.
    Chuang, C. -C.
    O'Malley, J. T.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E159 - E160
12345